Disease Information

General Information of the Disease (ID: DIS00132)

Type(s) of Resistant Mechanism of This Disease

IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Drug

Approved Drug(s)

4 drug(s) in total

Click to Show/Hide the Full List of Drugs

Clindamycin

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Irregularity in Drug Uptake and Drug Efflux (IDUE)		Click to Show/Hide
Key Molecule: ABC protein lsaC (lsaC-Unclear)			[1]
Resistant Disease	Streptococcus agalactiae infection [ICD-11: 1B21.2]
Molecule Alteration	Expression	Up-regulation	Molecule Info
Resistant Drug	Clindamycin		Drug Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Escherichia coli TOP10		83333
	Staphylococcus aureus ATCC 29213		1280
	Streptococcus agalactiae UCN70		1311
	Streptococcus agalactiae isolates		1311
	Streptococcus agalactiae BM132		1319
Experiment for Molecule Alteration	Whole genome sequence assay; Allelic frequency measurement assay
Experiment for Drug Resistance	Broth microdilution method assay
Mechanism Description	Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins.

Dalfopristin

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Irregularity in Drug Uptake and Drug Efflux (IDUE)		Click to Show/Hide
Key Molecule: ABC protein lsaC (lsaC-Unclear)			[1]
Resistant Disease	Streptococcus agalactiae infection [ICD-11: 1B21.2]
Molecule Alteration	Expression	Up-regulation	Molecule Info
Resistant Drug	Dalfopristin		Drug Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Escherichia coli TOP10		83333
	Staphylococcus aureus ATCC 29213		1280
	Streptococcus agalactiae UCN70		1311
	Streptococcus agalactiae isolates		1311
	Streptococcus agalactiae BM132		1319
Experiment for Molecule Alteration	Whole genome sequence assay; Allelic frequency measurement assay
Experiment for Drug Resistance	Broth microdilution method assay
Mechanism Description	Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins.

Lincomycin

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Irregularity in Drug Uptake and Drug Efflux (IDUE)		Click to Show/Hide
Key Molecule: ABC protein lsaC (lsaC-Unclear)			[1]
Resistant Disease	Streptococcus agalactiae infection [ICD-11: 1B21.2]
Molecule Alteration	Expression	Up-regulation	Molecule Info
Resistant Drug	Lincomycin		Drug Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Escherichia coli TOP10		83333
	Staphylococcus aureus ATCC 29213		1280
	Streptococcus agalactiae UCN70		1311
	Streptococcus agalactiae isolates		1311
	Streptococcus agalactiae BM132		1319
Experiment for Molecule Alteration	Whole genome sequence assay; Allelic frequency measurement assay
Experiment for Drug Resistance	Broth microdilution method assay
Mechanism Description	Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins.

Tiamulin

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Irregularity in Drug Uptake and Drug Efflux (IDUE)		Click to Show/Hide
Key Molecule: ABC protein lsaC (lsaC-Unclear)			[1]
Resistant Disease	Streptococcus agalactiae infection [ICD-11: 1B21.2]
Molecule Alteration	Expression	Up-regulation	Molecule Info
Resistant Drug	Tiamulin		Drug Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	Escherichia coli TOP10		83333
	Staphylococcus aureus ATCC 29213		1280
	Streptococcus agalactiae UCN70		1311
	Streptococcus agalactiae isolates		1311
	Streptococcus agalactiae BM132		1319
Experiment for Molecule Alteration	Whole genome sequence assay; Allelic frequency measurement assay
Experiment for Drug Resistance	Broth microdilution method assay
Mechanism Description	Expression of this novel gene, named lsa(C), in S. agalactiae BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 ug/ml), clindamycin (0.03 to 2 ug/ml), dalfopristin (2 to >32 ug/ml), and tiamulin (0.12 to 32 ug/ml), whereas no change in MICs of erythromycin (0.06 ug/ml), azithromycin (0.03 ug/ml), spiramycin (0.25 ug/ml), telithromycin (0.03 ug/ml), and quinupristin (8 ug/ml) was observed. The phenotype was renamed the LS(A)P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutilins.

References

Ref 1	Cross-resistance to lincosamides, streptogramins A, and pleuromutilins due to the lsa(C) gene in Streptococcus agalactiae UCN70. Antimicrob Agents Chemother. 2011 Apr;55(4):1470-4. doi: 10.1128/AAC.01068-10. Epub 2011 Jan 18.